Skip to main content
. Author manuscript; available in PMC: 2016 Dec 21.
Published in final edited form as: Pharmacol Ther. 2013 Jan 24;138(2):185–196. doi: 10.1016/j.pharmthera.2013.01.007

Table 2.

Classification of urological malignancies at diagnosis.

Tumor type 5-year survival according to pathological stage at diagnosis
Prostate Epithelial (>95%) Organ confined prostate cancer (T1–T2): 100%
Adenocarcinoma (95%)
Urothelial
Squamous
Basal cell
Other (<5%)		 Locally advanced prostate cancer (T3–T4): >95%
Metastatic prostate cancer (N+/M+): 29%
Bladder Epithelial (>95%) Superficial bladder cancer & carcinoma in situ (Ta/Tis/T1): >98%
Transitional cell carcinoma (>90%)
Squamous cell carcinoma (1–7%)
Adenocarcinoma (2–3%)
Other (<5%)		 Muscle-invasive bladder cancer (T2–T4): 63%–88%
Metastatic bladder cancer (N+/M+): 15%–46%
Kidney Renal cell carcinoma (>95%) Organ confined renal cell carcinoma (T1–T2): 81%
Clear cell renal carcinoma (75–80%)
Papillary renal cell carcinoma (10–15%)
Chromophobe renal cell carcinoma (5%)
Other (<5%)		 Locally advanced renal cell carcinoma (T3–T4): 53%–74%
Metastatic renal cell carcinoma (N+/M+): 8%
Testicular Germ cell tumors (90%) Testicular cancer confined to testis and epididymis (T1–T2): 99%
Seminoma (48%)
Non-seminomatous (42%)
Mixed NSGCT (10%)
Sex cord stromal tumors (3%)
Other (7%)		 Locally advanced testicular cancer (T3–T4): 96%
Metastatic testicular cancer (N+/M+): 72%

Abbreviations: is=in situ and NSGCT=non seminomatous germ cell tumor.

Survival data obtained from American and European Associations of Urology guidelines